A multicenter study of individuals who have symptoms of thyroid eye disease (also called Graves' orbitopathy) for fewer than six months and have not receieved any treatment for their eye symptoms other than lubricating eye drops. The purpose of this study is to evaluate the effectiveness, safety and tolerability of an investigational medication, insulin-like growth factor-1 receptor (IGF-1R), that may help to alleviate the symptoms of thyroid eye disease in adults, 18 to 75 years of age. Participation will involve up to 18 visits over a period of 19 months. There will also be two scheduled telephone calls between visits.
If you qualify and decide to particpate in the study, you will be assigned to one of two groups at random, similar to flipping a coin. Depending upon your group assignment, you will either be given the investigational medication or an inactive placebo that has no treatment value.
All study related exams, evaluations and either the investigational mediciation or the inactive placebo will be provided to qualified particpants at no cost. Financial compensation may also be provided to those who qualify to cover time and travel expenses related to the study.
To see if you qualify, learn more at GravesEyeDiseaseStudy.com
For further information: http://clinicaltrials.gov/ct2/show/NCT01868997?term=igf+thyroid+eye&rank=1
Christine Sinkey, BSN, CCRC (319) 353-8723
Participants in this study have been diagnosed with progressive metastatic Castration Resistant Prostate Cancer (CRPC). The purpose of this study is to compare the overall survival of patients with progressive metastatic CRPC treated with either a) enzalutamide only or b) enzalutamide with abiraterone and prednisone. Approximately 60 participants will take part in this study at the University of Iowa.
Clarine Halvorsen, 319-356-3944
This research study is for patients diagnosed with T-cell Acute Lymphoblastic Leukemia (ALL). ALL is a type of cancer that occurs in the bone marrow. It is a disease in which there is an uncontrolled growth of abnormal white blood cells, referred to as blasts. These abnormal cells crowd out the normal cells in the bone marrow. Sometimes these blasts cells can be found in the brain, spinal cord, and /or other organs of the body. Participants in this study have a type of ALL that places them in the Intermediate Risk group of T-cell ALL, which means that they have entered remission (less than 5% blasts in the bone marrow at the end of Induction therapy and 0.1-1% blasts detected by a test called flow cytometry) and are not in the Low or High Risk groups. Most subjects (about 60%) with T-cell ALL fall into the Intermediate Risk group.
Julie de la Garza, (319) 356-3749
Champion: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
HF Pressure Measurement System
The primary hypothesis is that the TREATMENT group will have a significantly lower rate of HF-related hospitalizations than the CONTROL group. ( Time Frame: 6 months). This trial is closed to enrollment and is follow-up phase.
This trial is closed to enrollment and continues in follow up phase.
Cardiomyopathy Treatment Program
Cynthia Larew RN 319-356-1028 pager # 2123
Who can apply: People diagnosed with breast cancer who are 65 or older
Purpose: develop a model of clinical and biological predictors of toxicity to adjuvant and neoadjuvant chemotherapy in older adults with breast cancer
Study Length: 2 years
Number of participants: 30
Michelle Arnold, 319-356-2778
Please help us improve your experience on our website by completing a brief survey
Yes, I'll give feedback No, Thanks
Your browser does not support iframes.